Figure 2From: Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups Progression-free survival. Progression-free survival in subgroup analyses per type of cytotoxic agent associated (A) and type of fluoropyrimidine administration (B).Back to article page